Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 1, Issue 2, Pages 265-275Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S1567-5769(00)00032-1
Keywords
class II; targeted antigen; dendritic cells; CD40
Categories
Funding
- NIA NIH HHS [AG14782] Funding Source: Medline
Ask authors/readers for more resources
We examined the efficacy of using monoclonal antibodies to target antigen (avidin) to different surface molecules expressed on antigen presenting cells (APC). In particular, we targeted CD40 to test whether the adjuvant properties of CD40 signaling combined with targeted antigen would result in enhanced serologic responses. We targeted avidin to class II as a positive control and to CD11c as a negative control. These surface proteins represent an ensemble of surface molecules that signal upon ligation and that are expressed on professional APC, in particular dendritic cells (DC). We observed that targeting class II molecules on APC was superior to targeting CD40, or CD11c. However, CD40 and CB11c could function as targets for antigen bound monoclonal antibodies under certain conditions. Interestingly, inclusion of anti-CD40 mAb with the targeting anti-class II-targeted antigens negatively affects humoral response, suggesting that CD40 signaling under certain conditions may suppress processing and/or presentation of targeted antigen. (C) 2001 Published by Elsevier Science B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available